Patients ( pts ) with HER@-positive ( gene amplification or increased copy numbers based on predefined criteria ) advanced GC were randomly allocated @:@ to receive LAP @mg per day @-@ plus capecitabine ( CAP ) @mg/m ( @ ) on days @-@ of a @-day cycle or LAP @mg monotherapy day @-@ after having failed on a platinum-based first-line therapy .